{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.0977","upperLimit":"0.0277","value":"-0.0350"},{"groupId":"OG001","lowerLimit":"-0.1572","upperLimit":"-0.0256","value":"-0.0914"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Intent-To-Treat Population includes all participants who are randomized into this study.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)","title":"Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}